In 2017, results from phase III trials demonstrated the impressive safety and efficacy of adjuvant targeted and immune therapies in patients with resectable stage III–IV melanoma, and raised questions about the surgical management of patients with microscopic sentinel-lymph-node metastases. For patients with unresectable disease, new overall survival data added to the debate about the relative benefits of single-agent anti-PD-1 versus combined anti-PD-1 and anti-CTLA-4 immunotherapy.
Subscribe to Journal
Get full journal access for 1 year
only $17.42 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Luke, J. J. et al. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat. Rev. Clin. Oncol. 14, 463–482 (2017).
Eggermont, A. M. et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 16, 522–530 (2015).
Eggermont, A. M. et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N. Engl. J. Med. 375, 1845–1855 (2016).
Weber, J. et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N. Engl. J. Med. 377, 1824–1835 (2017).
Long, G. V. et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N. Engl. J. Med. 377, 1813–1823 (2017).
Gershenwald, J. E. et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J. Clin. 67, 472–492 (2017).
Faries, M. B. et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N. Engl. J. Med. 376, 2211–2222 (2017).
Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23–34 (2015).
Wolchok, J. D. et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 377, 1345–1356 (2017).
Long, G. V. et al. Outcomes in patients (pts) treated with ipilimumab (ipi) after pembrolizumab (pembro) in KEYNOTE-006 [abstract]. Pigm. Cell Melanoma Res. 30, 76–156 (2017).
M.A.D. acknowledges funding support from the US National Cancer Institute (grants 1R01CA187076-02, 1U54CA224070-01, and 2T32CA009666-21), The Cancer Prevention and Research Institute of Texas (RP160183), the Melanoma Research Alliance, and the Melanoma Research Foundation. Both M.A.D and K.T.F. acknowledge funding support from the Dr Miriam and Sheldon G. Adelson Medical Research Foundation.
M.A.D. has served on advisory boards for BMS, Novartis, Roche/Genentech, Sanofi-Aventis, and Vaccinex, and has been the Principal Investigator of studies funded by grants to his institution from AstraZeneca, BMS, Oncothyreon, Roche/Genentech, and Sanofi-Aventis. K.T.F. has served on advisory boards for BMS, Merck, Novartis, and Roche/Genentech, and has received grant support from Novartis.
About this article
Cite this article
Davies, M., Flaherty, K. Moving treatments earlier to move further forwards. Nat Rev Clin Oncol 15, 75–76 (2018). https://doi.org/10.1038/nrclinonc.2017.183
Identification of immune-related biomarkers associated with tumorigenesis and prognosis in cutaneous melanoma patients
Cancer Cell International (2020)
International Immunopharmacology (2020)